Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Local Institution - Unk025, Anchorage, Alaska +165 locations
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
NCT06028932
Recruiting
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut
Conditions: Ovarian Carcinoma
Register for Updates
Cognitive Control Training for Extinction in PTSD
NCT06629064
Recruiting
The proposed study will test whether a working memory training (WMT) program improves fear extinction learning and its underlying neural circuitry in Veterans with posttraumatic stress disorder (PTSD). WMT is designed to improves the ability to maintain task-relevant information in mind. The project will further validate the relationship between working memory and fear extinction using novel computational and multivariate analyses that link to specific PTSD symptoms. If WMT can enhance fear exti... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/04/2024
Locations: VA San Diego Healthcare System, San Diego, CA, San Diego, California
Conditions: Post-Traumatic Stress Disorders, Stress Disorders, Traumatic, Post Traumatic Stress Disorder, PTSD, Trauma and Stressor Related Disorders
Register for Updates
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
NCT03671889
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
10/04/2024
Locations: Delray Medical Center & Florida Atlantic University, Delray Beach, Florida +9 locations
Conditions: Alzheimer Disease
Register for Updates
Mitigating the Pro-inflammatory Phenotype of Obesity
NCT04934228
Recruiting
The purpose of this study is to examine the hypothesize that 4 weeks of sympathetic nerve activity (SNA) inhibition (oral clonidine) will cause a significant reduction in circulating blood concentrations and endothelial cell expression of inflammatory markers (e.g., TNF-α, IL-6). Our study is a prospective study using a randomized, double-blinded design to test 4 weeks of SNA blockade (oral clonidine) compared with a BP-lowering control condition (diuretic, hydrochlorothiazide) or a placebo.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
10/04/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Blood Pressure, Diabetes, Obesity, Insulin Resistance, Diuretics Drug Reactions, Sympathetic Nerve Activity
Register for Updates
The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge from Ambulatory Surgery
NCT05676294
Recruiting
The primary objective of this phase 2 randomized controlled trial is to determine whether the pre-operative administration of olanzapine (5 mg PO) improves quality of recovery (assessed by the Quality of Recovery-40 (QoR-40) survey) on postoperative day 1 in patients having ambulatory surgery with general anesthesia. The secondary objectives of this study are to determine whether there are differences in quality of recovery on postoperative day 2, presence of post-discharge nausea, presence of... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
10/04/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Postoperative Nausea and Vomiting
Register for Updates
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
NCT06163391
Recruiting
This is a Phase 1, open-label, dose escalation study to assess the safety, tolerability, and preliminary efficacy of SOT201 as monotherapy for participants aged 18 years or above with advanced unresectable or metastatic solid tumors During dose escalation, the recommended dose(s) of SOT201 given every 3 weeks (Q3W) will be determined
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: MD Anderson Cancer Center, Houston, Texas +6 locations
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients with Inflammatory or Invasive Breast Cancer
NCT00477100
Recruiting
This trial studies the biospecimen and medical data collection in creating a research tissue registry in patients with inflammatory or invasive breast cancer. Collecting medical data and storing samples of blood, tissue, and stool from patients with inflammatory breast cancer to study in the laboratory may help doctors find better ways to treat and study inflammatory breast cancer in the future.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Banner - MD Anderson Cancer Center, Gilbert, Arizona +9 locations
Conditions: Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Second Primary Malignant Neoplasm
Register for Updates
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
NCT05203172
Recruiting
The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studies may participate the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona +56 locations
Conditions: Solid Tumors
Register for Updates
Problem-Solving Training for Concussion
NCT05837676
Recruiting
Mild traumatic brain injury (mTBI), also known as concussion, is a common injury sustained by Veterans. While most individuals who sustain mTBI experience a complete recovery within several weeks of injury, many Veterans with history of mTBI report frequent and long-lasting neurobehavioral complaints and functional impairment. Though research suggests that these outcomes are strongly influenced by co-occurring conditions such as post-traumatic stress disorder, depression, and chronic pain, evide... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: VA Western New York Healthcare System, Buffalo, NY, Buffalo, New York
Conditions: Brain Concussion
Register for Updates
Esophageal Temperature During PVI Using Q-DOT Micro
NCT06392932
Recruiting
This study will assess how two different ablation strategies, using two different ablation catheters during catheter ablation for paroxysmal atrial fibrillation, affect the temperature of the esophagus during ablation, and the risk of injury to the esophagus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Cedars-Sinai Smidt Heart Institute, Los Angeles, California
Conditions: Atrial Fibrillation Paroxysmal
Register for Updates
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620
NCT05456503
Recruiting
The investigators will compare PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal seniors.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
10/03/2024
Locations: Perelman Center for Advance Medicine, Philadelphia, Pennsylvania
Conditions: Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
Register for Updates